News

Artisan Bio, Inc., a stealth cell therapy engineering company, announced it has entered into a global research and collaboration agreement with Takeda Pharmaceutical Company Limited for…
Read More...

AstraZeneca and MSD Inc., Kenilworth, N.J., US announced that a supplemental New Drug Application for Lynparza (olaparib) in combination with bevacizumab has been accepted and granted…
Read More...

Galapagos NV and Fibrocor Therapeutics Inc. announced an expanded collaboration focused on novel targets in fibrosis, with Galapagos taking an equity stake in Fibrocor. Fibrocor is a…
Read More...

Clovis Oncology announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental New Drug Application (sNDA) for Rubraca (rucaparib) and granted…
Read More...

Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, announced that it has entered into a collaboration and license agreement with Japan Tobacco Inc. (JT) for…
Read More...

ASC Therapeutics announced that it has entered into a long-term strategic manufacturing partnership with Vigene Biosciences, a Maryland-based Contract Develop and Manufacturing…
Read More...

ProBioGen AG and Lava Therapeutics B.V. announced the closing of a cell line development and manufacturing agreement for Lava’s novel bispecific antibody lead candidate. Founded in…
Read More...

My Green Lab announced a collaboration with AstraZeneca to implement a global-scale green labs program across their research sites as part of their commitment to sustainability,…
Read More...

Astellas Pharma Inc., through its wholly-owned subsidiary Universal Cells, Inc, and Adaptimmune Therapeutics plc, a leader in cell therapy to treat cancer, announced that they have…
Read More...

MorphoSys AG and Incyte Corporation announced that the companies have entered into a collaboration and license agreement to further develop and commercialize MorphoSys' proprietary…
Read More...

Charles River announced a multi-year drug discovery collaboration with Takeda Pharmaceutical Company Limited. Together, Charles River and Takeda will launch multiple integrated programs…
Read More...

BioMotiv, a mission-driven pharma company part of The Harrington Project for discovery and development, and Atomwise, the leader in using artificial intelligence (AI) for small molecule…
Read More...

Coherus BioSciences, Inc. announced the Company has entered into a licensing agreement with Innovent Biologics, (Suzhou) Co., Ltd. to commercialize Innovent’s biosimilar candidate to…
Read More...

Alnylam Pharmaceuticals announced that the Company has initiated a rolling submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lumasiran, an…
Read More...

Zymeworks Inc. announced the initiation of a Phase 2 trial evaluating ZW25 combination therapy and an agreement with Pfizer which advances the study. Zymeworks’ HER2-targeted bispecific…
Read More...

eFFECTOR Therapeutics and Pfizer Inc. announced an exclusive worldwide license and collaboration agreement to develop small-molecule inhibitors of eukaryotic initiation factor 4E…
Read More...

Eli Lilly and Company and Dermira, Inc. announced a definitive agreement for Lilly to acquire Dermira for $18.75 per share, or approximately $1.1 billion, in an all-cash transaction.…
Read More...

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on multimodal, disease-modifying therapies for neurodegenerative diseases, reported that the previously…
Read More...

Iovance Biotherapeutics, a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, and Cellectis, a clinical-stage biopharmaceutical company focused on…
Read More...

PPD, Inc. (PPD) has expanded its operations and leadership team in China to provide enhanced clinical development, laboratory, regulatory, site conduct, patient access and post-approval…
Read More...